Voyager Therapeutics - VYGR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 18.24 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.92
▼ -0.09 (-1.50%)

This chart shows the closing price for VYGR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Voyager Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VYGR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VYGR

Analyst Price Target is $7.00
▲ +18.24% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Voyager Therapeutics in the last 3 months. The average price target is $7.00, with a high forecast of $9.00 and a low forecast of $6.00. The average price target represents a 18.24% upside from the last price of $5.92.

This chart shows the closing price for VYGR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Voyager Therapeutics. This rating has held steady since February 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
7/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 0 sell ratings
10/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2022Chardan CapitalBoost Target$4.00 ➝ $6.00High
1/3/2022UBS GroupLower Target$14.00 ➝ $6.00High
11/2/2021Chardan CapitalLower TargetNeutral$5.50 ➝ $4.00Low
10/7/2021Robert W. BairdUpgradeNeutral ➝ Outperform$6.00 ➝ $9.00Medium
8/11/2021BenchmarkLower TargetBuy$20.00 ➝ $9.00Low
7/1/2021Chardan CapitalReiterated RatingNeutralHigh
6/21/2021Compass PointInitiated CoverageBuy$45.00Low
5/13/2021Robert W. BairdReiterated RatingHold$6.00High
4/19/2021Morgan StanleyLower TargetEqual Weight$7.00 ➝ $6.00Medium
3/1/2021Robert W. BairdReiterated RatingOutperform ➝ Buy$18.00Low
2/26/2021Robert W. BairdDowngradeOutperform ➝ Neutral$18.00 ➝ $6.00High
2/3/2021WedbushDowngradeOutperform ➝ Neutral$13.00 ➝ $6.00High
2/3/2021Morgan StanleyLower TargetEqual Weight ➝ Hold$13.00 ➝ $7.00High
2/3/2021Chardan CapitalLower TargetNeutral$15.00 ➝ $6.50High
2/3/2021BTIG ResearchDowngradeBuy ➝ NeutralHigh
1/25/2021HC WainwrightInitiated CoverageBuy$12.00Medium
12/23/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$15.00 ➝ $10.00N/A
12/23/2020Raymond JamesDowngradeOutperform ➝ Market PerformN/A
11/11/2020BTIG ResearchLower Target$31.00 ➝ $18.00High
11/11/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
11/10/2020WedbushLower TargetOutperform$19.00 ➝ $13.00High
11/10/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$10.00High
11/10/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$28.00 ➝ $17.00High
10/13/2020WedbushLower TargetHold ➝ Outperform$24.00 ➝ $19.00High
8/14/2020Chardan CapitalReiterated RatingHold$15.00Medium
8/12/2020WedbushReiterated RatingBuy$24.00Low
8/4/2020HC WainwrightLower TargetBuy$18.00 ➝ $14.00High
5/13/2020NomuraReiterated RatingBuy$16.00Low
5/8/2020Chardan CapitalReiterated RatingHold$15.00Low
4/15/2020Morgan StanleyLower TargetEqual Weight$14.00 ➝ $13.00Low
3/30/2020Nomura SecuritiesLower TargetBuy$37.00 ➝ $16.00High
3/19/2020BenchmarkInitiated CoverageBuy$18.00High
3/6/2020Chardan CapitalReiterated RatingHold$20.00High
3/4/2020HC WainwrightLower TargetBuy$26.00 ➝ $18.00Medium
3/4/2020Morgan StanleyLower TargetEqual Weight$15.00 ➝ $14.00Medium
3/4/2020WedbushLower TargetOutperform$34.00 ➝ $27.00High
2/5/2020OppenheimerInitiated CoverageOutperform$26.00High
11/24/2019Evercore ISIReiterated RatingHold$18.00Medium
11/6/2019WedbushReiterated RatingOutperformMedium
11/6/2019CowenReiterated RatingBuyHigh
10/15/2019CowenReiterated RatingBuyLow
10/11/2019Morgan StanleyLower TargetEqual Weight$28.00 ➝ $26.00Low
8/13/2019Nomura SecuritiesReiterated RatingBuy$37.00High
8/12/2019HC WainwrightReiterated RatingBuy$26.00Medium
7/12/2019Morgan StanleyBoost TargetEqual Weight$21.00 ➝ $28.00Medium
6/20/2019Nomura SecuritiesBoost TargetBuy$26.00 ➝ $37.00High
6/18/2019WedbushBoost TargetOutperform$27.00 ➝ $36.00High
5/6/2019HC WainwrightReiterated RatingBuy$22.00Medium
3/5/2019Cantor FitzgeraldInitiated CoverageOverweight$27.00High
2/27/2019CowenReiterated RatingBuyHigh
1/15/2019HC WainwrightReiterated RatingBuy$21.00High
1/10/2019Chardan CapitalReiterated RatingNeutralMedium
1/8/2019BTIG ResearchLower TargetBuy ➝ Positive$23.00Low
11/30/2018HC WainwrightSet TargetBuy$25.00Low
11/9/2018HC WainwrightSet TargetBuy$25.00Medium
11/8/2018Robert W. BairdLower TargetOutperform ➝ Outperform$31.00 ➝ $27.00High
11/8/2018Morgan StanleySet TargetHold$13.00High
11/8/2018WedbushReiterated RatingOutperform$18.00 ➝ $28.00High
9/10/2018Morgan StanleyDowngradeOverweight ➝ EqualHigh
9/10/2018Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$27.00High
9/10/2018BTIG ResearchReiterated RatingBuy ➝ Buy$32.00Medium
8/8/2018HC WainwrightSet TargetBuy$30.00High
7/17/2018HC WainwrightSet TargetBuy$30.00High
6/21/2018Chardan CapitalReiterated RatingHold$30.00High
6/7/2018BTIG ResearchReiterated RatingBuy$32.00Low
6/4/2018HC WainwrightInitiated CoverageBuy$30.00High
5/13/2018BTIG ResearchReiterated RatingBuyHigh
5/11/2018WedbushUpgradeNeutral ➝ OutperformHigh
3/12/2018WedbushDowngradeOutperform ➝ Neutral$29.00High
3/12/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Buy$40.00High
3/11/2018BTIG ResearchReiterated RatingBuy$32.00High
2/21/2018WedbushBoost TargetOutperform$22.00 ➝ $29.00High
2/21/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$36.00 ➝ $39.00High
2/2/2018Morgan StanleyInitiated CoverageOverweight ➝ OverweightHigh
12/19/2017BTIG ResearchInitiated CoverageBuy$32.00High
11/28/2017Piper Jaffray CompaniesReiterated RatingOverweight$28.00Medium
11/20/2017WedbushReiterated RatingOutperform$22.00 ➝ $26.00N/A
10/31/2017Chardan CapitalReiterated RatingHold$17.00N/A
10/31/2017CowenReiterated RatingBuyN/A
10/31/2017WedbushReiterated RatingOutperform ➝ Positive$36.00 ➝ $31.00N/A
10/30/2017Robert W. BairdInitiated CoverageOutperform ➝ Outperform$31.00N/A
10/23/2017Stifel NicolausReiterated RatingBuy ➝ Buy$20.00 ➝ $31.00N/A
10/12/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$35.00N/A
(Data available from 10/1/2017 forward)

News Sentiment Rating

0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/5/2022
  • 6 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/4/2022
  • 6 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/4/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
6/3/2022
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/3/2022
  • 1 very positive mentions
  • 12 positive mentions
  • 5 negative mentions
  • 5 very negative mentions
8/2/2022
  • 6 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/1/2022
  • 2 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/1/2022

Current Sentiment

  • 2 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Voyager Therapeutics logo
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $5.92
Low: $5.81
High: $6.08

50 Day Range

MA: $6.35
Low: $5.57
High: $7.47

52 Week Range

Now: $5.92
Low: $2.46
High: $10.60

Volume

170,339 shs

Average Volume

468,754 shs

Market Capitalization

$228.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Voyager Therapeutics?

The following equities research analysts have issued stock ratings on Voyager Therapeutics in the last year: Chardan Capital, Robert W. Baird, StockNews.com, and UBS Group AG.
View the latest analyst ratings for VYGR.

What is the current price target for Voyager Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Voyager Therapeutics in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 18.2%. Robert W. Baird has the highest price target set, predicting VYGR will reach $9.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $6.00 for Voyager Therapeutics in the next year.
View the latest price targets for VYGR.

What is the current consensus analyst rating for Voyager Therapeutics?

Voyager Therapeutics currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VYGR will outperform the market and that investors should add to their positions of Voyager Therapeutics.
View the latest ratings for VYGR.

What other companies compete with Voyager Therapeutics?

How do I contact Voyager Therapeutics' investor relations team?

Voyager Therapeutics' physical mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company's listed phone number is (857) 259-5340 and its investor relations email address is [email protected] The official website for Voyager Therapeutics is www.voyagertherapeutics.com. Learn More about contacing Voyager Therapeutics investor relations.